Ranbaxy Attacks Recall Demand In Glass Particles Action

Law360, New York (February 20, 2013, 2:55 PM EST) -- Ranbaxy Laboratories Ltd. in New Jersey federal court Tuesday attacked a proposed class action targeting its generic version of Lipitor, questioning the honesty of patients allegedly harmed by pills potentially tainted with glass and saying a court-ordered larger recall would usurp regulators' authority.

In its brief opposing a preliminary injunction, the Indian drugmaker cast doubt on the reliability of four individuals who say they suffered harmful side effects, saying three of the patients reported gastrointestinal issues that are common side effects of cholesterol-lowering medicine atorvastatin. As...
To view the full article, register now.